Abstract

Artemisinin-hydroxychloroquine sulfate tablets (AH) are relatively inexpensive and a novel combination therapy for the treatment of all forms of malaria, especially aminoquinine drug-resistant strains of P. falciparum. Our aim was to assess the pharmacokinetics (PK) and toxicokinetics (TK) of AH following oral administration in Sprague Dawley rats and Beagle dogs by using the liquid chromatography tandem mass spectrometry methods (LC-MS/MS). The PK studies were carried out in eighteen rats at three doses and six dogs at three rounds of three doses after a single oral administration of AH. The TK studies in rats and dogs were accompanied by the 14-day repeated dosing studies. The PK results revealed that artemisinin was absorbed and cleared rapidly in rats with obvious gender difference and interindividual variability, and the systemic exposure with regard to AUC was positively correlated with the dosage in female rats. However, the kinetics parameters of artemisinin in dogs were not obtained because the plasma concentration was undetectable. The absorption and elimination of hydroxychloroquine in dogs and rats were relatively slow, and no gender difference was observed. The AUC of hydroxychloroquine showed a linear correlation with the dosage, but Cmax varied significantly among individuals. After 14-day repeated oral administration of AH, hydroxychloroquine shows an increase in systemic exposure and accumulation in rats and dogs, whereas the AUC and Cmax of artemisinin remarkably decreased in female rats due to its autoinduction metabolism. The TK results were basically consistent with the dose- and time-dependent toxic reaction in 14-day repeated dosing studies of AH in rats and dogs. The information from our studies could be helpful for further pharmacological and toxicological research and clinical application of AH.

Highlights

  • Malaria, caused by Plasmodium, is one of the most prevalent vector-borne diseases in the world

  • Typical chromatograms of rat blank plasma, blank plasma spiked with hydroxychloroquine or artemisinin, and the internal standard (IS) and dosed rat plasma samples are presented in Figure 1, and there is no significant interference from endogenous components at the retention times of hydroxychloroquine (0.73 min) and artemisinin (1.70 min)

  • Obvious gender differences in the pharmacokinetics and toxicokinetics of artemisinin were observed in Sprague Dawley (SD) rats with higher plasma exposure and lower clearance rate in female rats, which is similar to the previous pharmacokinetic studies of artemisinin in rats [11, 12]

Read more

Summary

Introduction

Malaria, caused by Plasmodium, is one of the most prevalent vector-borne diseases in the world. Artemisinin-based combination therapies (ACTs), combining an artemisinin or its derivatives with a partner drug, are recommended by the WHO as the first-line treatment for uncomplicated Plasmodium falciparum malaria. E role of the artemisinin compound is to reduce the number of parasites during the first three days of treatment (reduction of parasite biomass), while the role of the partner drug is to eliminate the remaining parasites (cure). Drugs compatible with artemisinins, such as piperquine phosphate, pyrimethamine, mefloquine, and amodiaquine, are widely used in the treatment of malaria but have developed resistance [2, 3]. ACTs are still effective in most cases In this regard, we hope to choose an antimalarial drug that is not widely used and is compatible with artemisinin to form a new and effective compound, which has broad application prospects

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call